arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

LB Pharmaceuticals Inc

LBRX Health Care Biotechnology: Pharmaceutical Preparations
$38.73
▼ -1.3% Today
as of Oct 23, 16:50 ET
Last 30 days -13.63% Sep 14 → Oct 23
$33.13 $36.28 $39.42 $42.56 $45.71 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$39.25
High
$39.73
Low
$38.29
Volume
$188,567
Avg Vol
$289,681
Mkt Cap
$1.1B
P/E (TTM)
—
Beta
—
52w High
$50.16
52w Low
$14.32
Div Yield
—
Shares Out
$29M

Recent Press Releases & News last 60 days · 2 items

Oct 11 · 01:15 Simply Wall St.
LB Pharmaceuticals (LBRX) Stock Fair Value Rises As LB 102 Outlook Shifts
Sep 4 · 10:15 Simply Wall St.
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment

LBRX earnings at a glance

LB Pharmaceuticals Inc (LBRX) is scheduled to report earnings on Thursday, November 5, 2026 — in 12 days. Analysts expect earnings per share of -$1.61, compared with -$0.61 in the same quarter last year (-164%). The options market is pricing a move of about ±14.7% after the report, a range of roughly $33.02 to $44.44 from today's $38.73. Over its last 4 reports the stock rose the next day 1 time and fell 3, moving ±3.0% on average; after the most recent report on Aug 11, 2026 it moved -1.1%. That means options currently expect more movement than LBRX has typically delivered. LBRX beat the consensus EPS estimate in 1 of its last 4 reported quarters. Implied volatility is currently 125%. The share price of $38.73 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$14
$50
68% of range
Avg surprise (last 4)
-25.0%
Avg reaction (last 4)
-1.1%
25% positive
Latest IV / EM
125%
EM ±14.7% · $35 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-39.49$-29.73$-19.97$-10.21$-0.45 Actual $-39.49Actual $-14.79Actual $-13.58Actual $-0.61Est $-0.57Actual $-0.45Est $-0.45Actual $-0.67Est $-0.75Actual $-1.71Est $-0.84 SepMarJunSep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-52M$-40M$-28M$-16M$-4M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Aug 11, 2026Jun/2026 $-1.71 $-0.84 -103.6% — -1.1% earnings
Tue May 12, 2026Mar/2026 $-0.67 $-0.75 +10.7% — +3.8% earnings
Thu Mar 26, 20268K 2026-03-26 $-0.45 $-0.45 0.0% — -2.8% earnings
Thu Nov 6, 2025Sep/2025 $-0.61 $-0.57 -7.0% — -4.3% earnings
Mon Jun 30, 2025Jun 2025 $-13.58 — — — — financials
Mon Mar 31, 2025Mar 2025 $-14.79 — — — — financials
Mon Sep 30, 2024Sep 2024 $-39.49 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER -$1.61-$0.61 -163.9%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income————————
Net income$-52M$-19M—$-4M$-5M$-5M—$-14M
EPS (diluted)$-1.71$-0.67—$-0.61$-13.58$-14.79—$-39.49

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$283M$321M$250M$270M——$23M—
Inventory————————
Total current assets$355M$389M$308M$316M——$29M—
Total assets$362M$393M$313M$321M——$34M—
Long-term debt————————
Total liabilities$29M$15M$12M$11M——$14M—
Total equity$332M$379M$301M$310M$-104M$-99M$-95M$-91M

Implied volatility — last 90 days

58%143%228%314%399% Jun 07 — IV 139% · EM ±19.3%Jun 11 — IV 162% · EM ±17.9%Jun 19 — IV 84% · EM ±18.5%Jun 22 — IV 87% · EM ±18.2%Jun 23 — IV 89% · EM ±18.3%Jun 24 — IV 92% · EM ±18.4%Jun 25 — IV 98% · EM ±19.2%Jun 26 — IV 99% · EM ±19.0%Jun 29 — IV 138% · EM ±24.5%Jun 30 — IV 127% · EM ±21.9%Jul 01 — IV 135% · EM ±22.6%Jul 02 — IV 120% · EM ±19.4%Jul 03 — IV 124% · EM ±19.4%Jul 06 — IV 119% · EM ±16.5%Jul 07 — IV 113% · EM ±14.9%Jul 08 — IV 133% · EM ±16.7%Jul 09 — IV 128% · EM ±15.1%Jul 10 — IV 140% · EM ±15.5%Jul 13 — IV 238% · EM ±19.8%Jul 14 — IV 255% · EM ±18.4%Jul 16 — IV 399% · EM ±16.7%Jul 20 — IV 114% · EM ±26.9%Jul 21 — IV 74% · EM ±17.2%Jul 22 — IV 92% · EM ±21.0%Jul 23 — IV 80% · EM ±18.1%Jul 24 — IV 84% · EM ±18.6%Jul 27 — IV 91% · EM ±19.0%Jul 28 — IV 84% · EM ±17.2%Jul 29 — IV 90% · EM ±17.9%Jul 30 — IV 62% · EM ±12.1%Jul 31 — IV 68% · EM ±13.0%Aug 03 — IV 79% · EM ±14.0%Aug 04 — IV 78% · EM ±13.4%Aug 05 — IV 68% · EM ±11.4%Aug 06 — IV 72% · EM ±11.6%Aug 07 — IV 81% · EM ±12.7%Aug 10 — IV 80% · EM ±11.0%Aug 11 — IV 85% · EM ±11.3%Aug 12 — IV 75% · EM ±9.4%Aug 13 — IV 90% · EM ±10.7%Aug 14 — IV 138% · EM ±15.3%Aug 17 — IV 102% · EM ±8.5%Aug 18 — IV 179% · EM ±12.9%Aug 19 — IV 176% · EM ±10.4%Aug 20 — IV 273% · EM ±11.4%Aug 24 — IV 65% · EM ±13.6%Aug 25 — IV 59% · EM ±12.0%Aug 26 — IV 74% · EM ±14.8%Aug 27 — IV 64% · EM ±12.6%Aug 28 — IV 73% · EM ±13.9%Aug 31 — IV 62% · EM ±10.9%Sep 01 — IV 64% · EM ±10.9%Sep 02 — IV 62% · EM ±10.3%Sep 03 — IV 78% · EM ±12.6%Sep 04 — IV 66% · EM ±10.3%Sep 07 — IV 75% · EM ±10.3%Sep 08 — IV 81% · EM ±10.7%Sep 09 — IV 100% · EM ±12.6%Sep 10 — IV 87% · EM ±10.3%Sep 11 — IV 103% · EM ±11.4%Sep 14 — IV 138% · EM ±11.5%Sep 15 — IV 164% · EM ±11.8%Sep 17 — IV 341% · EM ±14.2%Sep 21 — IV 86% · EM ±17.9%Sep 22 — IV 76% · EM ±15.5%Sep 23 — IV 78% · EM ±15.7%Sep 24 — IV 80% · EM ±15.6%Sep 25 — IV 76% · EM ±14.5%Sep 28 — IV 80% · EM ±14.2%Sep 29 — IV 116% · EM ±20.0%Sep 30 — IV 94% · EM ±15.6%Oct 01 — IV 129% · EM ±20.9%Oct 02 — IV 119% · EM ±18.7%Oct 05 — IV 136% · EM ±18.8%Oct 06 — IV 113% · EM ±14.9%Oct 07 — IV 62% · EM ±7.8%Oct 08 — IV 125% · EM ±14.7%

Sector peers

JANX
Janux Therapeutics, Inc.
$1.1B $16.66-1.6%
MNKD
MannKind Corporation
$1.1B $3.19+4.6%
OPK
Opko Health, Inc.
$1.0B $1.63+1.9%
PCRX
Pacira BioSciences, Inc.
$1.0B $36.42+0.2%
DMRA
Damora Therapeutics, Inc.
$1.2B $21.09-2.0%
KURA
Kura Oncology, Inc.
$949M $9.61-2.7%

LBRX earnings FAQ

When is LBRX's next earnings date?

LB Pharmaceuticals Inc is expected to report on November 5, 2026.

What is LBRX's expected move for earnings?

Options currently price a move of about ±14.7%, or $5.71 per share either way from $38.73.

How does LBRX stock usually react to earnings?

Across the last 4 reports the average next-day move was ±3.0%, up 1 times and down 3 times.

What EPS are analysts expecting from LB Pharmaceuticals Inc?

The consensus estimate is -$1.61 per share, versus -$0.61 a year ago.

What is LBRX's implied volatility?

LBRX's at-the-money implied volatility is about 125% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in